New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 16, 2017 - Ispen announced the FDA approval of Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults.
Download PDF
Return to publications
